CLVT news

Clarivate announced a voluntary tender offer to purchase up to $400M of 2028 Notes and up to $100M of 2029 Notes. The company, a leading global provider of transformative intelligence, is offering to purchase the notes via its wholly-owned subsidiary.

Clarivate's LS&H divestiture, completed early in Q3 2026, coincides with improved organic recurring revenue growth. The company updated its financial outlook to reflect the effect of this divestiture and its reduced leverage profile.

Clarivate sold its Life Sciences & Healthcare segment for $600M to Altaris simplifying its portfolio. This transaction advances the company's strategic transformation, strengthens its balance sheet and enhances financial flexibility, with updated guidance expected upon Q3 2026 results.

Clarivate announced terms for the cash tender offer for its 3.875% Senior Secured Notes due 2028, with a price of $975.15. The action is a strategic move to manage outstanding debt obligations.

Clarivate has commenced a cash tender offer for $75 million of its 3.875% Senior Secured Notes due 2028. The transaction, valued at the Reference Yield plus a fixed spread, reflects strategic debt management.

Clarivate appointed Michael Easton as Executive VP and CFO, succeeding Jonathan Collins. Easton brings 25 years of experience. The company announced Q2 2026 financial results.

Clarivate PLC signed a definitive agreement to divest specific business assets, a move that the market will interpret as a strategic shift in the company's portfolio.

Clarivate announced it is divesting its Life Sciences & Healthcare segment to Altaris LLC for $600 million. The deal aims to sharpen focus on AI-driven segments and improve financial flexibility.

Clarivate announced Simon Webster, former CEO of CPA Global, as the new President of its IP segment effective June 10, 2026, replacing Maroun Mourad. The appointment signals leadership continuity in the company's IP business during its Value Creation Plan execution.